Poster

Superior Hepatoprotective Effects of OPK-88006, a Novel GLP-1/Glucagon receptor dual agonist, to Semaglutide and Survodutide in the GAN Diet-Induced Obese and Biopsy-Confirmed Mouse Model of MASH

Background & aim:

OPK-88006 is a novel peptide-based, long-acting glucagon-like peptide-1 receptor (GLP1R)/glucagon receptor (GCGR) dual agonist in current preclinical development for metabolic diseases, including obesity and metabolic dysfunction-associated steatohepatitis (MASH).

The present study aimed to compare the therapeutic profile of OPK-88006, semaglutide (GLP1R monoagonist) and survodutide (dual GLP1R-GCGR agonist) in the translational Gubra Amylin NASH (GAN) diet-induced obese (DIO) and biopsy-confirmed mouse model of MASH with liver fibrosis.

Subjects

GAN DIO-MASH mouse Mouse Body weight Blood biochemistry Bioinformatics Metabolic dysfunction-associated steatohepatitis GLP-1 receptor Glucagon receptor Histopathology score Image analysis Immunohistochemistry (IHC)Liver biopsy Liver morphometry Next-generation sequencing RNA sequencing OPK-88006 Semaglutide Survodutide

Share this page

Resource Library

Related resources

Preclinical efficacy and clinical translatability of elafibranor in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH

Metabolic, biochemical, histological, and transcriptomic effects of Firsocostat in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH 

AI-assisted Gubra Histopathological Objective Scoring Technique (GHOST) for unbiased, fast and accurate assessment of disease severity in rodent models of NASH

Proof-of-concept testing of semaglutide in the GAN diet-induced obese and biopsy-confirmed mouse model of MASH

For further information

Contact us

Gubra

Hørsholm Kongevej 11B
2970 Hørsholm
Denmark

+45 3152 2650